Nuclear medicine and information systems vendor ADAC Laboratoriesreported sharply higher sales and net income for its second quarter(end-March). The Milpitas, CA, company posted revenues of $58.4million, a company record, compared with revenues of $44.7
Nuclear medicine and information systems vendor ADAC Laboratoriesreported sharply higher sales and net income for its second quarter(end-March). The Milpitas, CA, company posted revenues of $58.4million, a company record, compared with revenues of $44.7 millionin the second quarter of 1995. Net income rose to $3.9 million,compared with $2.8 million in the corresponding period a yearago.
Bookings also increased, jumping 36% to $61 million and addingto the company's backlog. Nuclear medicine product bookings were$40 million for the quarter, a strong increase over the $31 millionin the same period last year but lower than the $48 million inthe first quarter of 1996. ADAC chairman and CEO David Lowe saidthat the drop was most likely due to a seasonal softening of theU.S. nuclear medicine market, as well as a reduction in servicecontract renewals commonly experienced in the second quarter.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.